--- schema_version: "secwatch.filing_event.v1" accession: "0001654954-23-007162" form_type: "8-K" ticker: "EDSA" cik: "0001540159" company_name: "Edesa Biotech, Inc." filed_at: "2023-05-24T23:59:59+00:00" generated_at: "2026-06-14T15:56:54.177741+00:00" event_type: "leadership" sentiment: "neutral" materiality_score: 0.55 calibrated_materiality_score: 0.55 confidence: "high" source: SEC EDGAR --- # Edesa Biotech CFO to retire July 15; shareholders approve share increase for equity plan ## Summary - CFO Kathi Niffenegger to retire effective July 15, 2023; will remain as advisor and on subsidiary board. - Shareholders approved amending 2019 Equity Incentive Plan to increase shares available by 1,380,000. - All seven director nominees elected at annual meeting with 7.06-7.26M votes each. - Advisory vote on executive compensation passed with 6.55M for, 0.55M against. - Appointment of MNP LLP as independent auditor approved with 10.23M for, 0.53M withheld. ## SEC filing metadata - accession: 0001654954-23-007162 - form_type: 8-K - ticker: EDSA - cik: 0001540159 - company_name: Edesa Biotech, Inc. - filed_at: 2023-05-24T23:59:59+00:00 - event_type: leadership - sentiment: neutral - materiality_score: 0.55 - calibrated_materiality_score: 0.55 - confidence: high - sec_items: 5.02, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495423007162/0001654954-23-007162-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495423007162/edsa_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001654954-23-007162 - JSON: https://secwatch.observer/filing/0001654954-23-007162.json - Plain text: https://secwatch.observer/filing/0001654954-23-007162.txt ## Key facts - Executive change Kathi Niffenegger departed as Chief Financial Officer at Edesa Biotech, Inc.. - Action: intention to retire - Role: Chief Financial Officer source text: On May 23, 2023, Kathi Niffenegger, the Chief Financial Officer of the Company, notified the Company of her intention to retire from her position and responsibilities as Chief Financial Officer effective July 15, 2023. evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495423007162/0001654954-23-007162-index.htm - Shareholder Votes Edesa Biotech, Inc. shareholders approved Advisory Vote on Executive Compensation. - Proposal: say on pay - Outcome: passed source text: Proposal No. 2 - Advisory Vote on Executive Compensation The shareholders approved, on an advisory basis, the executive compensation of the named executive officers as disclosed in the Proxy Statement, by the following vote. For Against Abstain Broker Non-Votes 6,549,767 550,638 320,148 3,334,009 evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495423007162/0001654954-23-007162-index.htm - Shareholder Votes Edesa Biotech, Inc. shareholders approved Appointment of MNP LLP as the Company’s Auditors and Independent Registered Public Accounting Firm for the Ensuing Year. - Proposal: auditor ratification - Outcome: passed source text: Proposal No. 4 - Appointment of MNP LLP as the Company’s Auditors and Independent Registered Public Accounting Firm for the Ensuing Year Based upon the following votes, the shareholders approved the appointment of MNP LLP as the Company’s independent registered public accounting firm until the close of the 2024 annual meeting of shareholders or until a successor is appointed. For Withhold 10,225,858 528,704 evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495423007162/0001654954-23-007162-index.htm - Shareholder Votes Edesa Biotech, Inc. shareholders approved Election of the Company’s Directors. - Proposal: director election - Outcome: passed source text: Proposal No. 1 – Election of the Company’s Directors Based upon the following votes, the shareholders elected Joan Chypyha, Sean MacDonald, Patrick Marshall, Pardeep Nijhawan, Frank Oakes, Charles V. Olson and Carlo Sistilli to serve as members of the Company’s board of directors until the annual general meeting of shareholders to be held in 2024 or until their successors are duly elected and qualified. For Withhold Broker Non-Votes Joan Chypyha 7,116,425 304,128 3,334,009 Sean MacDonald 7,260,834 159,719 3,334,009 Patrick Marshall 7,116,744 303,809 3,334,009 Pardeep Nijhawan, MD 7,058,239 362,314 3,334,009 Frank Oakes 7,064,233 356,320 3,334,009 Charles Olson, D.Sc. 7,116,984 303,569 3,334,009 Carlo Sistilli, CPA, CMA 7,116,801 253,752 3,334,009 evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495423007162/0001654954-23-007162-index.htm - Shareholder Votes Edesa Biotech, Inc. shareholders approved Amendment to 2019 Equity Incentive Compensation Plan. - Proposal: equity plan - Outcome: passed source text: Proposal No. 3 - Amendment to 2019 Equity Incentive Compensation Plan The shareholders approved the amendment to the Company’s 2019 Equity Incentive Compensation Plan (the “2019 Plan”) to increase the number of shares available for issuance under the 2019 Plan by 1,380,000 shares as disclosed in the Proxy Statement, by the following vote. For Against Abstain Broker Non-Votes 6,490,800 530,086 399,667 3,334,009 evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000165495423007162/0001654954-23-007162-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.